Details of the Drug Combinations

General Information of This Drug (ID: DMWP1BH)

Drug Name

Tazemetostat DMWP1BH

Synonyms

EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-

Indication

Disease Entry	ICD 11	Status	REF
Follicular lymphoma	2A80	Approved	[1]
Brain and central nervous system tumour	2A00.11	Phase 2	[2]
Malignant rhabdoid tumour	2A00.1Y	Phase 2	[3]
Mesothelioma	2C51.2	Phase 2	[4]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
Diffuse large B-cell lymphoma	2A81	Phase 1/2	[4]
Synovial sarcoma	2B5A	Phase 1	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Belinostat + Tazemetostat	DC77XDW	Belinostat	Recurrent B-Cell Non-Hodgkin Lymphoma	[5]
Enzalutamide + Tazemetostat	DC4IVPN	Enzalutamide	Metastatic Prostate Cancer	[6]
Itraconazole + Tazemetostat	DCWVYM0	Itraconazole	All Malignancies	[7]
Lenalidomide + Tazemetostat	DCGJ3NV	Lenalidomide	Relapsed Hematologic Malignancy	[8]
Rifampicin + Tazemetostat	DCTMVIN	Rifampicin	All Malignancies	[7]
Talazoparib + Tazemetostat	DC8HJ86	Talazoparib	Metastatic Prostate Cancer	[9]
Tazemetostat + Umbralisib	DC9HD1Z	Umbralisib	Recurrent Follicular Lymphoma	[10]
Venetoclax + Tazemetostat	DCL9LMM	Venetoclax	Lymphoma, Non-Hodgkin	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DrugCom(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	ClinicalTrials.gov (NCT05627245) Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
6	ClinicalTrials.gov (NCT04179864) A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
7	ClinicalTrials.gov (NCT04537715) Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer
8	ClinicalTrials.gov (NCT05205252) A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
9	ClinicalTrials.gov (NCT04846478) Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
10	ClinicalTrials.gov (NCT05152459) Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
11	ClinicalTrials.gov (NCT05618366) Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma